price month
preview investor feedback post-
uk denmark us code
novo nordisk report result may detail
estim figur highlight follow key point ahead
cs estim broadli line consensu
ahead consensu expect sale higher assumpt
insulin partial off-set lower forecast higher
ozemp sale lower victoza sale vs con oper profit
behind consensu higher cost ozemp
roll-out launch oral sema
fx tailwind expect compani fx algorithm suggest fx
tailwind sale oper profit expect see sale
oper profit
remind ozemp sale minim given limit
pipelin fill access impact part reform
impact impact oper profit
posit impact sale nnti
cost follow submiss oral sema api cost move
 onto balanc sheet lower cost due lower
guidanc guidanc cer oper profit growth
expect chang guidanc
feedback post upgrad outperform
larg receiv posit recept follow upgrad novo
howev also receiv pushback outlin three
upgrad novo ahead offici reform legisl earli
investor view time upgrad reform
announc earli investor believ overwhelm initi
reaction healthcar reform sell major player us
rather identifi winner loser howev dust
settl post-reform agre novo key beneficiari
manag unlik promot benefit us reform
investor believ novo unlik talk volum gain could get
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
remov rebat given enter elect cycl
price deterior investor believ
inevit price pressur class us occur quicker
manag expect common theme post
lilli weak trulic number key focu novo
result lilli result trulic sale light consensu due
neg one-off lower net realis us price past novo
confid competit price class given
small size rel class look see confid
charl martineau univers toronto figur cse vs consensu drug summari
diabet obes total
compani mention price
